Background: We report midterm outcomes with the GORE Iliac Branch Endoprosthesis (IBE; W. L. Gore & Associates, Flagstaff, Ariz) in the U.S. investigational device exemption (IDE) trial and comparatively assess outcomes in the IDE trial with outcomes in a real-world population of patients treated in the Gore Global Registry for Endovascular Aortic Treatment (GREAT).
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Questions Society for Vascular Surgery Phone: 800-258-7188; education@vascularsociety.org reinterventions through 6 months were compared in the IDE trial and GREAT registry. Clinical and core laboratoryassessed imaging outcomes were assessed in the IDE trial through 2 years.
Results: GREAT patients were significantly older (P ¼ .01) and of shorter height (P < .001) and lower weight (P < .001). There were also significantly more women treated in GREAT vs the IDE trial (8% vs 1%; P ¼ .02). Thirteen GREAT patients (14%) and 4 of 35 continued access IDE patients (11%) had bilateral IBE placement (P ¼ .70). IDE patients were more likely to be treated with percutaneous access methods (55% vs 40%; P ¼ .04). Three IDE patients and three GREAT patients underwent 1-month reintervention, with two IDE reinterventions (2.1%) and one GREAT reintervention (1.6%) for thrombotic events. Five additional patients in each study underwent reintervention through 6 months (5% vs 5%; P ¼ .92), all for nonthrombotic events. Internal iliac limb patency was 93.6% (95% confidence interval, 86.4%-97.1%) at 12 and 24 months in the IDE study. Subset analyses of the 10 IDE and GREAT patients with #6-month reintervention vs 181 intervention-free patients found that acute myocardial infarction (P ¼ .01), nonpercutaneous access (P ¼ .01), and surgical conduit use (P < .001) were associated with reintervention through 6 months. In the IDE trial, 3.4% and 4.1% of patients underwent reintervention at 12 months and 24 months, respectively, all for treatment of type II endoleaks. At 24 months, 8.7% of IDE patients exhibited abdominal aortic aneurysm sac expansion; 21.7% exhibited abdominal aortic aneurysm sac regression. No patients exhibited CIA aneurysm sac expansion; 45% exhibited CIA aneurysm sac regression.
Conclusions:
Midterm IDE outcomes and 6-month outcomes in the worldwide GREAT registry suggest that endovascular aortic aneurysm repair with concomitant CIA aneurysm repair with the IBE device is safe and effective. Thrombotic events are uncommon and are concentrated in the first month after the index procedure, and they typically can be resolved with endovascular reintervention. (J Vasc Surg 2019;69:367-77.)
Keywords: Iliac branch device; EVAR; Aneurysm; Iliac; Endovascular A variety of novel solutions for endovascular treatment of common iliac artery (CIA) aneurysms, which often occur in patients with abdominal aortic aneurysms (AAAs), have been studied recently.
1,2 CIA and aortoiliac aneurysms pose a formidable challenge to obtaining adequate distal seal during endovascular aneurysm repair. These anatomic factors can be addressed by open surgical repair; however, open surgical repair exposes these patients to increased risk for morbidity and mortality, making extension of endovascular repair to these more challenging anatomies highly desirable. Ligation or embolization of the internal iliac artery (IIA) with extension of endograft coverage to the external iliac artery has been widely used but exposes patients to an increased risk of buttock claudication and erectile dysfunction, particularly when bilateral embolization is required. 3, 4 Although serious complications are rare, hypogastric embolization is also associated with a significantly higher rate of bowel ischemia and renal failure. 5, 6 The current recommendation from both the European and American Societies is to preserve flow in at least one IIA or the inferior mesenteric artery. The European Society for Vascular Surgery considers this mandatory to avoid early complications. Six-month outcomes with the IBE in the U.S. investigational device exemption (IDE) trial confirmed safety and early effectiveness of the device and have been previously reported. 10 One significant limitation of iliac branch devices is the anatomic requirements, which restrict application to some patients. 11 Performance of these devices in real-world populations is therefore of critical interest to practitioners. Our purpose is twofold: to report midterm outcomes in the IDE trial with both the pivotal phase and continued access cohorts and to comparatively assess the clinical trial outcomes with real-world outcomes in the Gore Global Registry for Endovascular Aortic Treatment (GREAT).
METHODS
Study design. Full details of the IDE study design and inclusion and exclusion criteria and a description of the IBE device have been published previously. 10 Briefly, the IDE trial was a U.S. prospective, multicenter, single-arm study that aimed to assess the safety and effectiveness of the IBE as concomitant treatment with the Excluder endoprosthesis in patients with CIA and aortoiliac aneurysms. The trial enrollment of the pivotal phase and continued access phase was completed in 2015 and 2016, respectively. The trial is registered on ClinicalTrials. gov (NCT01883999). A Clinical Events Committee adjudicated safety and effectiveness end point events, and baseline and follow-up imaging were core laboratory assessed (AortaCore; University of Wisconsin-Madison, Madison, Wisc). Bilateral IBE treatment was allowed only in the continued access arm of the study. GREAT is a worldwide registry designed to capture the real-world performance of Gore aortic devices for a variety of aortic diseases in the United States and outside the United States as well as data on worldwide follow-up patterns, serious adverse event (SAE) management, and standard of care. GREAT included only commercial use of Gore aortic devices and did not include U.S. IDE trial participants. GREAT completed enrollment in 2016 with >5000 patients enrolled; follow-up through 10 years will be collected (and is currently ongoing). The study is registered on ClinicalTrials.gov (NCT01658787) and conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Inclusion criteria were limited to a signed informed consent form, indication for endovascular treatment, and satisfying local age requirements. There were no anatomic exclusion criteria, and off-label use of the device was permissible, per the investigator's discretion. Event management and follow-up regimen were also ultimately per the investigator's discretion. Events and imaging are site adjudicated and reviewed, with weekly sponsor review and periodic assessment from an independent oversight and safety monitoring board. 
RESULTS
IDE and GREAT baseline characteristics. The IDE trial enrolled 64 patients in the pivotal arm and 35 patients in the continued access arm from February 2015 to March 2016 for a total population of 99 patients. Ninety-two patients (28 U.S. patients, 64 patients outside the United States) were treated with the IBE in GREAT from 2013 to 2016. Baseline demographics are compared in Table I . Whereas IDE patients were almost exclusively male, GREAT patients had a higher proportion of women (P ¼ .02), of smaller stature (P < .001) and lower weight (P < .001), and were older (P ¼ .01). Comorbidities were more prevalent in IDE patients, who presented with significantly higher incidence of congestive heart failure (P ¼ .04), hypercholesterolemia (P ¼ .007), and peripheral vascular disease (P < .001). A comparison of iliac measurements was constrained by the limited number of GREAT patients with available iliac measurements and was not eligible for statistical comparison; however, available aortic and iliac measurements from GREAT were similar in comparison to IDE patients (Table II) .
Procedural characteristics. A significantly higher percentage of IDE patients received the device through percutaneous access (P ¼ .04). Open femoral access, with or without use of a conduit, was more common in a global registry setting (Table III) . Thirteen GREAT patients (14%) had bilateral IBE placement compared with 4 (11%) of 35 continued access IDE patients eligible for bilateral IBE treatment (P ¼ .70). Six GREAT patients (6.5%) and one IDE patient (1%) were implanted with the IBE device without the internal iliac component (IIC; P ¼ .04). In the IDE trial, this was due to placement of an iliac extender into the IIA as opposed to the IIC. In the IDE trial, this patient and one additional patient who underwent concomitant femoral artery repair were in violation of exclusion criteria and ineligible for effectiveness end point analyses; one further device deviation occurred in the IDE trial, wherein one patient had an aortic extender placed as a bridge between the Excluder contralateral leg endoprosthesis and the IBE device. Four GREAT patients received contralateral limbs with distal diameters outside the range deemed compatible with deployment of the IBE device (23 or 27 mm). Procedural survival was 100% in both cohorts. A slight majority of GREAT patients (51/92 [55%]) were considered to have device use outside the instructions for use (IFU) for one or more Excluder or IBE criteria (Table IV) . Take Home Message: Analysis of 2-year outcomes after GORE Iliac Branch Endoprosthesis (IBE) implantation in 99 patients enrolled in the U.S. investigational device exemption trial and 6-month outcomes in 92 patients from the Gore Global Registry for Endovascular Aortic Treatment (GREAT) registry revealed that use of the IBE device for endovascular iliac aneurysm repair is safe and effective, with rare thrombotic events, mostly in the first months, that can be treated with endovascular techniques. Recommendation: IBE endograft should be used for endovascular treatment of iliac aneurysm associated with aortic aneurysm.
ARTICLE HIGHLIGHTS
Thirty-day safety outcomes and mortality. Of the 98 IDE patients treated, no patients experienced any primary safety end point major adverse events through 30 days. Of the 92 GREAT patients, two patients (2.2%) experienced SAEs that qualified as major adverse events per the IDE safety end point definitions. One patient had a stroke 3 days after the index procedure and one patient died of unknown cause 22 days after the index procedure. There was no further mortality through 6 months in GREAT. In the IDE trial, there were three nonaneurysm-related deaths within 6 months (two cardiac arrest, one cancer).
Reinterventions. Five IDE patients (5.1%; 4 of 5 were continued access patients) and five GREAT patients (5.4%) underwent reintervention through 6 months (P ¼ .92). Reintervention rates and indications are presented in Table V . Two IDE patients (2.2%) underwent reintervention for treatment of type II endoleaks (both underwent coil embolization) at 6 months. In GREAT, a single patient (1.8%) was treated for type IA endoleak (proximal extension) at 1 month. At 6 months, two GREAT patients (3.6%) underwent reinterventions (one for a type IB endoleak and one for a type II endoleak).
Thrombotic events that resulted in reintervention all occurred in the first month in both cohorts, with two IDE patients (2.1%; both continued access patients) and one GREAT patient (1.8%) experiencing a thrombotic event. One continued access patient experienced thrombosis of an IBE external iliac artery limb 1 day after the index procedure that was treated with thrombectomy. A second continued access patient experienced buttock claudication and thrombosis of bilateral external iliac arteries that was treated with thrombectomy. Neither patient exhibited further thrombotic events through 12-and 24-month imaging follow-up, respectively. One GREAT patient experienced thrombosis of the right external iliac artery 27 days after the index procedure and was treated with a femoral-femoral bypass 3 weeks later.
Subset analyses. A subset analysis was conducted comparing baseline and procedural characteristics of IDE and GREAT patients with reintervention through 6 months (n ¼ 10) with IDE and GREAT patients remaining intervention free (n ¼ 181; Table VI) . Overall, the baseline patient profile was similar in patients ultimately undergoing reintervention vs those intervention free; however, patients with history of acute myocardial infarction (within 6 months of the procedure) were significantly more likely to undergo reintervention through 6 months (P ¼ .01). Patients with nonpercutaneous access were also significantly more likely to have #6-month reintervention (P ¼ .01), particularly patients using surgical conduits (P < .001). Buttock claudication and nonserious device occlusion in the IDE trial. At 1 month, 8 (31%) of 26 patients with staged procedures to occlude the contralateral IIA experienced unilateral buttock claudication on the side of the intentionally occluded IIA; no other patients experienced buttock claudication at 1 month. An additional one patient had worsening of pre-existing erectile dysfunction. Five patients (5.2%) had asymptomatic IIC or IIA occlusion at 1 month; four occurred in the IIC and one involved occlusion due to distal native vessel atherosclerosis. At 6 months, two additional patients (2%) experienced new-onset buttock claudication. In one patient, claudication followed IIC occlusion noted at 1 month; the other patient, a continued access patient with bilateral IBE placement, exhibited bilateral buttock claudication without device occlusion. No further serious or nonserious thrombotic events, buttock claudication, or erectile dysfunction was reported through 2 years in the IDE trial.
Late outcomes in the IDE trial. No IDE patients exhibited any further thrombotic events beyond 6 months. Internal iliac limb patency was 93.6% (95% confidence interval [CI], 86.4%-97.1%) at 12 and 24 months in the IDE study (Fig 1) . Freedom from type I and type III endoleaks in the IDE trial was 100% through 2 years. The core imaging laboratory identified 58 patients with type II endoleaks at the 1-month assessment. At 6 months, three new type II endoleaks were observed, with no new type II endoleaks observed at 12-or 24-month follow-up. Full details on type II endoleak incidence and treatment through 2 years are presented in the Supplementary Table (online only) . Interventions in the IDE trial after 6 months were limited to embolization of type II endoleaks: three patients (3.4%) at 12 months and two patients (4%) at 24 months, both of whom had previously undergone embolization at 12 months. Freedom from reintervention was 90.4% through 2 years (95% CI, 81.3%-95.2%; Fig 2) . No device migration, component separation, or stent graft fracture was observed through 2 years. Two patients had device compression observed at 1 month. One was due to excessive oversizing when an iliac extender was used in the IIA instead of the IIC; the other device compression was the result of coverage of the proximal end of the IIC by the bridging iliac limb component. One of these patients was considered a technical failure at the time of the implantation procedure as the patient did not receive both components of the device (iliac extender placed into IIA instead of IIC). An additional three patients died through 2-year follow-up, all from non-aneurysm-related causes. One death occurred subsequent to thoracic aortic type B dissection 19 months after the index procedure. Freedom from mortality was 91.8% (95% CI, 82.2%-96.3%) through 2 years in the IDE trial (Fig 3) . Sac diameter change in the IDE trial. At 12 and 24 months, AAA sac regression occurred in 19% and 22% of patients, respectively (Table VII) . CIA aneurysm sac regression was also more prevalent at 12 and 24 months, with 33% and 45% exhibiting CIA aneurysm sac regression, respectively, and no patients observed with CIA diameter expansion at either time point. AAA sac expansion was observed in 2% and 9% of patients at 12 and 24 months, respectively. All patients with AAA sac expansion had type II endoleaks and two patients underwent embolization.
DISCUSSION
Promising midterm and long-term outcomes for treatment of iliac artery aneurysm using iliac branch devices have previously been published [12] [13] [14] [15] [16] [17] [18] ; however, most of these reports are limited to single-center experiences. We previously reported similar excellent but shortterm results for the IBE from the IDE trial pivotal cohort with follow-up through 6 months. 10 In this report, we demonstrate continued excellent outcomes for iliac aneurysm treatment using the IBE through 2 years from both the pivotal and continued access arms of the IDE trial as well and comparable early outcomes from real-world use of the IBE within the GREAT registry.
Importantly, in the IDE trial, device primary patency at 2 years was 93.6%, and 91.8% of patients remained free from reintervention through 2 years. Midterm data from the IDE trial and the real-world experience show a low incidence of serious endoleaks or thrombotic events. In the IDE trial, no type I or type III endoleaks were identified by core laboratory assessment through 2 years, and 91.8% of patients remained free from reintervention through 2 years. Data from the trial and the registry showed a low incidence of devicerelated thrombotic events requiring intervention, all presenting within the first 30 days with no additional thrombotic events during late follow-up. Only 3 of the total of 191 patients (1.6%) in both the IDE trial and the GREAT registry underwent reintervention for thrombotic events, and all were for external iliac artery occlusions. In the IDE trial, 5 of 99 patients (5.1%) experienced occlusion of the IIC, but all were asymptomatic and none underwent reintervention. All of the IIC occlusions were asymptomatic when they were first detected on the 30-day follow-up imaging studies. The early occurrence of these events suggests that they were likely due to technical or anatomic factors. Possible causes for failure that were identified included excessive oversizing of the IIC component (outside of the IFU guidelines) and landing One patient had an iliac extender placed instead of the IIC; this was one of two device deviations in the IDE trial, the other being one patient with an aortic extender placed bridging between the contralateral leg and the IBE. Twenty-eight GREAT patients were treated in the United States and 64 were treated outside the United States. Mean length of stay was equivalent in U.S. GREAT patients and IDE patients; treatment outside the United States was significantly longer, probably because of differing treatment protocols outside the United States.
of the end of the IIC or external iliac limbs at a site of arterial tortuosity or at a site of significant atherosclerotic occlusive disease. These observations emphasize the importance of appropriate selection of patients and adherence to the manufacturer's IFU guidelines for optimal outcomes. We also sought to compare trial outcomes with those in a real-world registry with a more diverse population of patients and off-label device use in >50% of cases. GREAT patients were significantly older, smaller, and shorter, although surprisingly, comorbidity burden was more severe in IDE patients. Baseline anatomic characteristics were similar across the two studies, although there were some notable variations in procedural characteristics. Despite these differences, clinically significant outcomes in the two studies through 6 months were similar. Further long-term follow-up in GREAT will determine whether thrombotic events are limited to the initial few months after device implantation, as observed in the IDE trial. Another goal of comparison between trial and registry outcomes was to analyze common baseline and procedural characteristics in patients with reintervention through 6 months vs those without reintervention. This analysis demonstrated that patients with acute myocardial infarction (<6 months) and patients treated with a nonpercutaneous approach were significantly more likely to undergo reintervention within 6 months. It is not clear why an acute myocardial infarction before the procedure would be associated with a higher risk of an IBE procedure-related reintervention, but this is an observation, and our findings should not imply causality.
Nonpercutaneous access was common in patients who underwent reintervention. Four of five IDE patients with reintervention through 6 months had nonpercutaneous access (all open femoral access). All five GREAT patients with reintervention through 6 months had nonpercutaneous access: three patients had surgical or endovascular conduits and two had open femoral access (one primary, one secondary). A recent analysis by Buck et al 19 found that femoral cutdown access was significantly more common in patients undergoing concomitant procedures and that a concomitant procedure during endovascular aneurysm repair was the only predictor for percutaneous access failure by multivariate analysis. Whereas percutaneous access was commonly used in IDE patients, open femoral access was the most common method used in GREAT. Femoral cutdown access has been associated with a higher rate of vascular complications and early events, such as access vessel thrombosis. 20, 21 It is highly likely, though not proven, that open surgical access selects far more complex and diseased anatomies that preclude percutaneous access. Whereas the advantages to percutaneous approaches have been documented in previous studies, 19 they may not be suitable for patients with advanced external iliac and femoral artery occlusive disease who require adjunctive open surgical procedures. Stringent anatomic criteria for iliac branch devices, particularly iliac diameter requirements, limit the application of this therapy to a majority of patients. 11 An analysis by Pearce et al 11 found that a majority of patients would be considered ineligible for the IBE or Zenith iliac branch device (Cook Medical, Bloomington, Ind) on the basis of anatomic exclusion criteria, although more would be eligible for the IBE. Inadequate CIA diameter was the most common reason for exclusion from treatment with the IBE. These criteria may be particularly restrictive for women, who have notably smaller iliac diameters. [22] [23] [24] The number of women treated with the iliac branch device in GREAT, although low at 8%, was still higher than the single female patient (1%) enrolled in the IDE trial. The much higher rate of men treated with the IBE in the IDE trial and GREAT is partly due to iliac aneurysms occurring at a higher rate in men. 25 One large analysis of U.S. hospital records found that iliac artery aneurysms occurred at a male to female ratio of 25:1. 26 Men are more likely to develop AAAs and CIA aneurysms than women are; however, they are also more likely to be eligible for endovascular treatment of aortic or iliac aneurysms. A total of 10 cases of new-onset buttock claudication were observed in the IDE trial through 2 years. Most occurred early and were not on the same side as the Distal aortic diameter outside treatment range 11 (12) Infrarenal neck <15 mm 3
Aortic neck angle >60 degrees 6 (7) IBE, Iliac Branch Endoprosthesis. Categorical data are expressed as number (%).
Patients were considered off-label because of anatomic characteristics outside IFU-specified treatment ranges or because of device use outside IFU specifications. Patients inputted as off-label because of "unapproved pathology" (n ¼ 31) are not included in the counts as "unapproved pathology" in GREAT may only indicate where site investigators did not input the iliac disease into a patient's case report form. a Thirteen GREAT patients had outside IFU use of the IBE on one or more criteria; these patients may also have been off-label per Excluder criteria. Breakdown of number of patients off-label per solely IBE criteria is not available. b Thirty-eight patients had outside IFU use of the Excluder device but were on-label for the IBE.
IBE device. Eight of 10 cases occurred within 1 month of the index procedure and were contralateral to the IBE device in patients who underwent staged procedures to intentionally occlude the contralateral IIA. The incidence of new-onset buttock claudication on the side of the IBE device was low, with 2 of 99 patients (2%) reporting buttock claudication at 6-month followup; one patient had occlusion of the IIC noted earlier at One patient required intervention at 1 month and 6 months.
b "Other events" through 1 month consisted of a left external iliac artery dissection in the IDE trial. One GREAT patient required early and late reintervention for a persistent type B aortic dissection and is counted in both windows in the category of other events. Initial reintervention consisted of placement of an additional endograft; second reintervention consisted of implantation of EndoAnchors (Medtronic, Santa Rosa, Calif). 1-month follow-up, and one patient with bilateral IBE devices reported bilateral buttock claudication without device occlusion. Notably, 31% of the 26 IDE patients who underwent staged procedures to occlude the contralateral IIA developed buttock claudication on the side of the intentionally excluded IIA. This rate is nearly identical to the reported rate of buttock claudication after IIA occlusion observed in the literature. 3 One change since the previous report is the allowance of bilateral IBE placement in the continued access cohort of the IDE trial. Four IDE patients (11%) and 13 GREAT patients (14%) underwent bilateral IBE treatment.
Of note in our previous report was the relatively high number of type II endoleaks observed through 6 months in the original IDE pivotal trial population. With the expanded cohort, early rates were nearly identical. Beyond 6 months, no new type II endoleaks were identified, and the number of persistent type II endoleaks diminished by roughly 10% at each follow-up window.
A total of five IDE patients ultimately had reintervention for a type II endoleak through 2 years. Type II endoleaks are notoriously difficult to assess, and their clinical significance is undetermined. With the GREAT registry, we are only aware of the rate of site-reported type II endoleaks undergoing reintervention. Similar to the IDE trial, the rate of reintervention for type II endoleaks is very low (one patient through 6 months). Despite the high incidence of type II endoleaks, AAA sac expansion was noted in only 2% and 9% of IDE patients at 12-and 24-months, respectively, and CIA aneurysm sac expansion ipsilateral to the IBE device was not observed. Moreover, at 2 years, a decrease of sac diameter of 5 mm or more was seen in 45% of patients. This suggests that most type II endoleaks are benign and that trends shifting toward watchful waiting as opposed to aggressive reintervention are appropriate.
Limitations. This retrospective comparison of the IDE trial and GREAT registry is significantly limited by different study designs and data collection methodologies. Consequently, several end points cannot be compared, such as rate of nonserious events like buttock claudication, endoleaks not intervened on (ie, type II endoleaks), and data on contralateral IIA procedures. Furthermore, as a worldwide registry, GREAT does not have core laboratory-assessed imaging data or Clinical Events Committee-adjudicated events, making formal comparison of any imaging end points inappropriate. This is a significant though inherent limitation to any comparison of IDE trial and registry data sets. Moreover, because the GREAT patients were significantly older and of shorter height and lower weight than the IDE patients, the populations may be inherently different and may reflect underlying anatomic differences between U.S. and European patients. The lower prevalence of comorbidities in the GREAT patients may either indicate additional differences between the study populations or reflect differences in the rigor of data capture between the two different studies. The comparison is also limited to the length of follow-up currently available in GREAT patients implanted with the IBEd6 months, on average. In both studies, a lack of collected data on certain baseline anatomic characteristics, such as iliac tortuosity and calcification, is a further limitation. The comparison of baseline and procedural characteristics between patients requiring reintervention in both studies was post hoc and exploratory, and no adjustment was made for multiple testing. Its findings should be viewed in this context and require confirmation from future, prospective studies.
CONCLUSIONS
Through 2-year follow-up, the IBE demonstrates durable preservation of iliac artery flow in the treatment of CIA and aortoiliac aneurysms. Device and vessel thrombotic events were few and concentrated in the first 6 months after implantation. Comparison of the IDE trial and GREAT registry cohorts through 6 months reveals differences in procedural technique; however, the rate of reintervention and SAEs were infrequent and similar through 6 months. An analysis of IDE trial and GREAT patients undergoing reintervention found that acute myocardial infarction and nonpercutaneous access methods may identify a group of patients at higher risk for early reintervention.
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